Cellulose nanofiber sheets enable analysis of EVs, and miRNAs within them, offering potential for cancer treatment and personalised medicine.
List view / Grid view
Researchers have been able to customise nanoparticles to target biological entities, like tumours and viruses.
Researchers have discovered a molecule that binds to a cancer cell protein, stopping growth of breast and ovarian tumours.
In this interview with Drug Target Review’s Izzy Wood and Dr Isaac Klein, Chief Scientific Officer at Dewpoint Therapeutics, discuss the innovative potential of condensate biology in revolutionising drug discovery. By targeting disease-driving condensates, Dewpoint’s research pushes boundaries by offering new hope for tackling diseases like ALS and colorectal cancer.
Japanese study has identified three previously unknown membrane proteins in ovarian cancer, using a new detection method consisting of nanotechnology and imaging techniques.
A recent study from researchers at the University of California examines the BRCA2 gene, which plays a crucial role in repairing damaged DNA, and possible links with increased risk of breast and ovarian cancer.
Ovarian cancer breakthrough: the potential of rhenium tricarbonyl (TRIP) as a promising anti-tumour drug
In this exclusive article, Drug Target Review’s Izzy Wood highlights ground-breaking ovarian cancer research, after speaking with Dr Benjamin Neuditschko, from the Institute Krems Bioanalytics at IMC Krems.
A new approach using CAR T-cell therapy is suggested by Swedish researchers as an effective treatment for ovarian cancer.
US researchers found that the severity of muscle wasting from cancer is related to the type, size and location of the tumour, in mice.
Researchers have discovered a new cancer immunotherapy approach that shrinks solid tumours.
The University at Buffalo has received a $2.3 million grant from the US National Cancer Institute to identify metabolic vulnerabilities of ovarian cancer and to develop potential treatments for the disease.
Researchers have found how ovarian cancer tumours defy immunotherapy, identifying new molecular targets that might boost immune response.
New research has discovered metabolic mechanisms that contribute to how ovarian cancer escapes from immune attack and how combination therapies can exploit these pathways to improve ovarian cancer treatment.
The new study looked at the network of gene-gene interactions associated with cancer onset and progression to identify therapeutic targets.